To Increase-or Not to Increase-the Dose?

A brief discussion of dose increase versus unchanged continuation of antidepressants after initial treatment failure in patients with depression.

Related Videos
Related Content

Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms

February 6th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder

January 25th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

CRP as a Biomarker of Antidepressant Efficacy

January 20th 2023

How to Navigate and Treat ‘New Year Depression’ in Your Patients

January 18th 2023

Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms

February 6th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder

January 25th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

CRP as a Biomarker of Antidepressant Efficacy

January 20th 2023

How to Navigate and Treat ‘New Year Depression’ in Your Patients

January 18th 2023

Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms

February 6th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder

January 25th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

CRP as a Biomarker of Antidepressant Efficacy

January 20th 2023

How to Navigate and Treat ‘New Year Depression’ in Your Patients

January 18th 2023
Advertise
Contact Us
Editorial
Terms and Conditions
Privacy Policy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.